Distribuzione geografica
Continente #
NA - Nord America 108
EU - Europa 104
AS - Asia 22
OC - Oceania 12
SA - Sud America 6
AF - Africa 1
Totale 253
Nazione #
US - Stati Uniti d'America 97
GB - Regno Unito 44
IT - Italia 21
DE - Germania 18
AU - Australia 12
CA - Canada 10
CN - Cina 4
FI - Finlandia 3
FR - Francia 3
IN - India 3
JP - Giappone 3
AL - Albania 2
AR - Argentina 2
BR - Brasile 2
CL - Cile 2
EE - Estonia 2
IE - Irlanda 2
PL - Polonia 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
IQ - Iraq 1
KZ - Kazakistan 1
LK - Sri Lanka 1
NL - Olanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 253
Città #
London 40
San Francisco 24
Redmond 20
Rome 18
Council Bluffs 15
Toronto 8
Melbourne 6
Seelze 5
Boydton 4
Haikou 4
Canberra 3
Hanover 3
Helsinki 3
Los Angeles 3
Oklahoma City 3
Paris 3
Sydney 3
Tokyo 3
Dublin 2
Lodz 2
New Delhi 2
Tallinn 2
Tirana 2
Almaty 1
Amsterdam 1
Berlin 1
Boardman 1
Buenos Aires 1
Central District 1
Centurion 1
Charlotte 1
Chicago 1
Colombo 1
Columbia 1
Dhaka 1
Frankfurt am Main 1
Hicksville 1
Lisbon 1
Lomas de Zamora 1
Manila 1
Markham 1
Minsk 1
Naples 1
Quilpué 1
Reston 1
Riyadh 1
Rockville 1
Sarajevo 1
Singapore 1
Swansea 1
Totale 205
Nome #
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 12
Pharmacology of Cardio-Oncology 12
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 11
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 10
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 8
Anthracycline Cardiotoxicity 8
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 8
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 7
Matters of the heart: The case of TNF-alpha targeting drugs. 7
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 7
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 7
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 6
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 6
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 6
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 6
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 6
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 6
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 6
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 5
Doxorubicin degradation in cardiomyocytes 5
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 5
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 5
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 5
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 5
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 5
Anthracycline Cardiotoxicity 5
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 5
What is cardiotoxicity? 4
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 4
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 4
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 4
Anthracyclines 4
Cardio-oncology in clinical studies and real life 4
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 4
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 4
Predictors of early or delayed diastolic dysfunction after anthracyclines-based or nonanthracycline chemotherapy: a pharmacological appraisal. 4
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 4
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 4
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 3
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 3
Cancer drugs and QT prolongation: weighing risk against benefit 3
Do you know pixantrone? 3
Isavuconazole: case report and pharmacokinetic considerations 3
Cardiotoxicity of antitumor drugs 3
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 3
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 3
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 3
The concomitant management of cancer therapy and cardiac therapy 3
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 3
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 3
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 3
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 3
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 3
Pharmacological Foundation of Cardio-Oncology 2
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 2
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implication for cardiotoxicity of doxorubicin-taxane chemotherapies 2
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 2
An introduction to the metabolic determinants of anthracycline cardiotoxicity 2
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 2
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 2
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 2
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 2
Minimal sampling colistin pharmacokinetics in critically ill patients 2
Molecular determinants of the reduced cardiotoxicity of epirubicin 2
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 2
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 2
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 2
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 2
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 1
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 1
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 1
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 1
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 1
The reality of pixantrone in real life 1
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 1
Translating molecular mechanisms into clinical facts 1
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 1
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 1
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 1
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 1
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 1
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 1
Totale 332
Categoria #
all - tutte 10.508
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.508

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022223 0 4 0 0 0 0 1 94 4 0 5 115
2022/202360 2 1 1 4 2 2 15 0 3 7 22 1
2023/202449 11 36 2 0 0 0 0 0 0 0 0 0
Totale 332